FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

  • In US
  • 2019-11-14 21:22:22Z
  • By Reuters

(Reuters) - A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

The panel on Thursday voted 16-0 in favor of expanding approval, potentially opening up a multi-billion dollar opportunity for the company which has only one drug, Vascepa, in the market.

The company's shares were halted ahead of the vote.

The FDA, which is slated to announce its final decision on the label expansion by Dec. 28, is not mandated to follow the recommendation of the panel, but generally does.

Vascepa, a highly purified omega-3 fatty acid derived from fish oil, won U.S. approval in 2012 to lower high levels of triglycerides, a type of blood fat that can increase the risk of heart disease.

"There is no doubt this is a medication that could benefit a substantial portion of the U.S. and meets an unmet need," said Dr. Jack Yanovski of the National Institutes of Health.

In the United States, cardiovascular disease leads to one in every three deaths, with annual treatment costs in excess of $500 billion, according to Amarin.

Patients with high triglycerides, who also have complications like diabetes, are especially vulnerable to recurring cardiovascular complications.

The drug has earlier won the vote of confidence from major medical communities including the American Heart Association, American Diabetes Association as a treatment to help lower the chance of heart attacks and strokes.

(Reporting by Saumya Sibi Joseph and Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)


More Related News

Trump still sees hydroxychloroquine as promising against COVID-19 -White House
Trump still sees hydroxychloroquine as promising against COVID-19 -White House
  • US
  • 2020-07-09 18:48:19Z

U.S. President Donald Trump continues to see a malaria drug, hydroxychloroquine, as a promising drug to be used to prevent infection with the coronavirus, the White House said on Thursday, though the U.S. Food and Drug Administration has said its efficacy and safety were unproven. "The president has always said that he sees hydroxychloroquine as a very promising prophylactic but that every person should not take it unless they get a prescription from their doctor," White House spokeswoman Kayleigh McEnany said at a news conference. Trump told reporters in May he had started taking hydroxychloroquine after two White House staffers tested positive for COVID-19.

Dems Fear Trump Will Rush Vaccine to Boost Re-Elect
Dems Fear Trump Will Rush Vaccine to Boost Re-Elect

When Trump administration officials leading the response to the coronavirus pandemic came to Capitol Hill last week, they were grilled for hours on everything from the reopening of schools to the efficacy of wearing masks.But as the hearing wound down, Sen. Tina Smith (D-MN) posed an altogether different type of question to Dr. Stephen Hahn, the head of the Food and Drug Administration. Could he, Smith asked, promise that the administration wouldn't rush a vaccine simply to help the president's re-election chances?A first-term Democrat, Smith hardly has a reputation as a congressional bomb-thrower-which was just one reason that her question stood out during an otherwise staid hearing. But...

Coronavirus (COVID-19) Update: Daily Roundup
Coronavirus (COVID-19) Update: Daily Roundup

Coronavirus (COVID-19) Update: Daily RoundupPR NewswireSILVER SPRING, Md., July 8, 2020SILVER SPRING, Md.

Philip Morris Scores FDA Approval For
Philip Morris Scores FDA Approval For 'Modified Risk' Labeling

The U.S. Food and Drug Administration has now authorized the marketing of Philip Morris International's (PM) "IQOS Tobacco Heating System" as modified risk tobacco products (MRTPs). Shares in PM rose 3.3% in Tuesday's trading.This marks the second set of products ever to be authorized as MRTPs and the first tobacco products to receive "exposure modification" orders- which permits the marketing of a product as containing a reduced level of or exposure to a substance or as being free of a substance when the issuance of the order is expected to benefit the health of the population.PM will still need to conduct postmarket surveillance and studies to determine whether the MRTP orders continues...

Three more hand sanitizers on FDA
Three more hand sanitizers on FDA's 'toxic' list. One already on the list gets recalled

The FDA's warning list of hand sanitizers that have methanol or might have methanol grew by three as one sanitizer on the list got recalled Monday night.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: US